参考文献/References:
[1] Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management[J].Lancet,2011, 378(9786):169-181.
[/br][2] Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103(2):137-149.
[/br][3] Packham DK, Alves TP, Dwyer JP, et al.Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC(Diabetes Mellitus Treatment for Renal Insufficiency Consortium)database[J]. Am J Kidney Dis, 2012, 59(1):75-83.
[/br][4] Nakagawa T. Is endothelial dysfunction more deleterious than podocyte injury in diabetic nephropathy?[J].Kidney Int, 2013, 83(6):1202-1203.
[/br][5] Gilbert RE. The endothelium in diabetic nephropathy[J]. Curr Atheroscler Rep,2014,16(5):410.
[/br][6] Liu X, Zang P, Han F, et al. Renal protective effects of induction of haem oxygenase-1 combined with increased adiponectin on the glomerular vascular endothelial growth factor-nitric oxide axis in obese rats[J].Exp Physiol, 2015,100(7):865-876.
[/br][7] Nakagawa T, Sato W, Kosugi T, et al. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy[J]. J Diabetes Res, 2013,2013:184539.
[/br][8] von Leitner EC, Klinke A, Atzler D, et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase[J].Circulation,2011,124(24): 2735-2745.
[/br][9] Nakagawa T, Sato W, Glushakova O, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy[J].J Am Soc Nephrol, 2007, 18(2): 539-550.
[/br][10] Brosius FC, Coward RJ. Podocytes, signaling pathways, and vascular factors in diabetic kidney disease[J]. Adv Chronic Kidney Dis, 2014, 21(3):304-310.
[/br][11] Nazir N, Siddiqui K, Al-Qasim S, et al.Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways[J].BMC Med Genet, 2014,15:103.
[/br][12] El Eter EA, Al-Masri AA. Adrenomedullin mediates early phase angiogenesis induced diabetic nephropathy in STZ diabetic rats[J]. Eur Rev Med Pharmacol Sci,2014,18(22):3534-3543.
[/br][13] Tahara A, Tsukada J, Tomura Y, et al.Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion[J].Neuropeptides, 2011,45(2):105-111.
[/br][14] Hou N, Huang N, Han F, et al. Protective effects of adiponectin on uncoupling of glomerular VEGF-NO axis in early streptozotocin-induced type 2 diabetic rats[J]. Int Urol Nephrol, 2014, 46(10):2045-2051.
[/br][15] Feliers D, Chen X, Akis N, et al.VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells[J].Kidney Int, 2005, 68(4):1648-1659.
[/br][16] Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis[J]. Acta Physiol(Oxf), 2006, 187(4): 433-446.
[/br][17] You H, Gao T, Cooper TK, et al. Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy[J]. Am J Physiol Renal Physiol, 2015,[Epub ahead of print].
[/br][18] Deng J, Wu G, Yang C, et al. Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats[J].J Transl Med, 2015,13:53.
[/br][19] Nakagawa T, Johnson RJ. Endothelial nitric oxide synthase [J]. Contrib Nephrol, 2011, 170: 93-101.
[/br][20] Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice[J]. J Am Soc Nephrol, 2006, 17(10): 2664-2669.
[/br][21] Bauer PM, Fulton D, Boo YC, et al. Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase [J]. J Biol Chem, 2003, 278(17): 14841-14849.
[/br][22] Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease[J]. Arterioscler Thromb Vasc Biol, 2004, 24(3):413-420.
[/br][23] Komers R, Schutzer WE, Reed JF, et al. Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney[J]. Diabetes, 2006, 55(6): 1651-1659.
[/br][24] Li H, Li H, Bao Y, et al. Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-κB pathway in rat aorta[J]. Int J Cardiol, 2011,152(2):218-224.
[/br][25] Sun X, Yu Y, Han L. High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats[J].Int Urol Nephrol, 2013, 45(4):1197-1207.
[/br][26] Wang B, Yu Y, Han L. Adiponectin improves endothelial dysfunction caused by elevated FFAs levels, partially through cAMP-dependent pathway[J]. Diabetes Res Clin Pract, 2012, 97(1):119-124.
[/br][27] Nagano K, Ishida J, Unno M, et al. Apelin elevates blood pressure in ICR mice with L-NAME-induced endothelial dysfunction[J].Mol Med Rep, 2013, 7(5):1371-1375.
相似文献/References:
[1].2007年糖尿病新进展学习班将举办[J].国际内分泌代谢杂志,2007,(04):226.
[2]李英,段惠军.Raf/MEK/ERK信号转导通路在糖尿病肾病发生发展中的作用[J].国际内分泌代谢杂志,2007,(04):264.
[3]张红 章向成 朱大龙.炎性反应与糖尿病肾病[J].国际内分泌代谢杂志,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
Zhang Hong*,Zhang Xiangcheng,Zhu Dalong..Role of inflammation in diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
[4]邵滢,王秋月.Mir-217/Sirt1通路与糖尿病肾病[J].国际内分泌代谢杂志,2015,(02):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
Shao Ying,Wang Qiuyue..Mir-217 / Sirt1 pathway and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
[5]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[6]任慧雯,王秋月.Epac-Rap1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
Ren Huiwen,Wang Qiuyue..Epac-Rap1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
[7]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
[8]陈堃,刘超,陈国芳,等.糖尿病肾病诊断标志物研究进展[J].国际内分泌代谢杂志,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
Chen Kun,Liu Chao,Chen Guofang,et al.Urinary biomarkers for diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
[9]任慧雯,王秋月.Vasohibin-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
Ren Huiwen,Wang Qiuyue..Vasohibin-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
[10]安丽,王秋月.Visfatin与胰岛素抵抗及糖尿病肾病的发病机制[J].国际内分泌代谢杂志,2015,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
An Li,Wang Qiuyue..Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]